Article written by mjn-neuro

Our project does not originate in a hospital research centre or a university. It is born from the grassroots, from the patient, from their needs, experiences and, why not say it, from their fears.

When we began our journey 7 years ago, we could not imagine how difficult it could be to market a medical device, with the necessary quality certifications, and that it was able to warn before an epileptic seizure. But we did know that the solution we propose will have a positive impact on the 3 levels we discussed previously: personal, environmental and social.

During these 7 years, at the same time that we have grown as a project, we have developed a structured way of managing our Social Impact. We have not made this journey alone, from these lines we want to thank the ship2B foundation, for all the support we have received in various areas of our project, and especially in the management of our Social Policy.

In the document attached, Theory of Social Change, we outline what is the problem that people who have refractory epilepsy face, what is the solution that we propose, (our mjn-SERAS device) and how we are going to positively impact our entire environment. But in addition, we express the need to combat the social stigma that still burdens epilepsy.

Finally, we would like to say that our Social Impact Policy determines mjn-neuro‘s actions in all areas. We could define mjn-neuro as the awareness of the impact it makes on society and the will to maximize that impact: qualitatively, seeking excellence in all the actions that are carried out. And quantitatively, trying to make mjn-neuro a global company that can help people with epilepsy all over the world.

We are very happy that mjn-neuro stands out as a project, within an entrepreneurial ecosystem, as a reference when it comes to managing its impact. And for us it has been a great experience to be able to explain our experience in the CataloniaBio & Healthtech session within the “Lessons Learned” on May 9th.

Leave a Reply

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!


    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.
    CPSP20103CAT.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.

    ¡Inscríbete!

      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.
      CPSP20103CAT.